Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Author(s): Riccardo Panella Added: 11 months ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
CardioNerds @AHA23: An Extended Duration Short-Interfering RNA Targeting Lp(a)
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 1 year ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more

Heart Failure

Prevention & Chronic Conditions
SUCCESS PTA: 12-Month Data from SELUTION SLR™ DEB
Author(s): Michael Lichtenberg Added: 2 weeks ago
12 Month Outcomes of the SUCCESS PTA Study show consistent safety and effectiveness in claudicant and CLTI patients when using the SELUTION SLR™ drug eluting balloon.Dr Michael Lichtenberg (Vascular Centre Clinic Arnsberg, Arnsberg, DE) joins us to discuss the SUCCESS PTA study, a prospective, observational global registry evaluating the SELUTION SLR DEB in 723 patients across Europe, Asia and… View more

Intervention

Vascular Disease and Surgery
TCT 24: The INFINITY-SWEDEHEART Trial
Author(s): David Erlinge Added: 6 months ago
TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients… View more

Intervention
PERFORMANCE II: Two-Year Outcomes
Author(s): William Gray Added: 3 weeks ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego… View more

Vascular Disease and Surgery
ESC 24: OCCUPI: OCT-Guided Coronary Intervention in Complex Lesions
Author(s): Byeong-Keuk Kim Added: 8 months ago
ESC Congress 24 — OCCUPI trial finds OCT-guided PCI more effective than angiography-guided PCI in reducing heart-related events.We are joined onsite at ESC 24 by Dr Kim Byeoung-Keuk (Yonsei University College of Medicine, Seoul, SK) to discuss the results of the OCCUPI trial (NCT03625908), which aims to evaluate the clinical benefits of optical coherence tomography (OCT)-guided percutaneous… View more

Imaging & Diagnostics

Intervention
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 1 month ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
Management of Left Main Coronary Artery Disease
Author(s): Gabriel Torres-Ruiz , Nuria Mallofré-Vila , Paola Rojas-Flores , et al Added: 1 year ago

Prevention & Chronic Conditions

Intervention
TCT 23: IFR SWEDEHEART
Author(s): Matthias Gotberg Added: 1 year ago
TCT 23 - We are joined by Dr Matthias Götberg (Lund University, SE) to discuss recent findings from a study of the SWEDEHEART Registry, where the long-term outcomes of iFR vs FFR guided coronary revascularization were compared. Results suggest that in a national registry analysis of 42887 patients investigated with iFR or FFR with 5-year follow-up, similar outcomes were observed in MACE, all… View more

Prevention & Chronic Conditions

Intervention
ESC 23: The OCTOBER Trial
Author(s): Niels Ramsing Holm Added: 1 year ago
ESC 2023 — Dr Niels Ramsing Holm (Aarhus University, DK) outlines the findings from the OCTOBER trial (NCT03171311). The OCTOBER trial (Aarhus University Hospital Skejby, Abbott) aimed to compare the median two-year clinical outcome after optical coherence tomography (OCT) guided percutaneous coronary intervention (PCI) as compared to angiographic-guided PCI. This was an investigator-initiated… View more

Intervention